Middle East Journal of Cancer

Cytoreductive Surgery plus Mitomycin-Based Hyperthermic Intraperitoneal Chemotherapy for a Patient with History of Right Hemicolectomy due to Mucinous Colorectal Adenocarcinoma with a Background of Myeloma Multiple: A Case Report

Articles in Press

Document Type : Case Report(s)

Authors

Kağan Gökçe 1
Murat Üner 1
Nur Adil 1
Mehrdad Sheikhvatan 2

1 Department of General Surgery, Surgical Oncology Unit, Istanbul Okan University, Faculty of Medicine, İstanbul, Turkey

2 Medical College, Tehran University of Medical Sciences, Tehran, Iran

10.30476/mejc.2026.110623.2404
Abstract
Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) using mitomycin C is an established locoregional treatment for selected patients with peritoneal metastases due to mucinous colorectal adenocarcinoma. Management becomes increasingly complex when such malignancies occur in individuals with concurrent hematologic disorders, such as multiple myeloma. We report a patient with recurrent mucinous colorectal adenocarcinoma who underwent right hemicolectomy followed by CRS and mitomycin-based HIPEC. The patient's medical history was notable for multiple myeloma, raising concerns regarding immune dysfunction, perioperative risks, and postoperative recovery. Complete cytoreduction was achieved, and HIPEC was administered without significant perioperative complications. Subsequent pathology and fluorodeoxyglucose positron emission tomography-computed tomography examination performed 3 months post-surgery showed no signs of malignancy. This case highlights the feasibility of CRS and HIPEC in patients with recurrent mucinous colorectal adenocarcinoma in the setting of coexisting multiple myeloma. It illustrates the potential oncologic benefit of mitomycin-based HIPEC in addressing peritoneal disease from mucinous colorectal carcinoma.

Highlights

Kağan Gökçe (goolge scholar)

Keywords

Multiple myeloma
Colorectal Neoplasms
Hemicolectomy
Case Report
Subjects

Please cite this article as: Gökçe K, Üner M, Adil N, Sheikhvatan M. Cytoreductive surgery plus mitomycin-based hyperthermic intraperitoneal chemotherapy for a patient with history of right hemicolectomy due to mucinous colorectal adenocarcinoma with a background of myeloma multiple: A case report. Middle East J Cancer. 2026: in press. doi: 10.30476/mejc.2026.110623.2404.

  1. Luo C, Cen S, Ding G, Wu W. Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. Cancer Commun (Lond). 2019;39(1):13. doi: 10.1186/s40880-019-0361-0. PMID: 30922401; PMCID: PMC6440160.
  2. Qi GX, Zhao RX, Gao C, Ma ZY, Wang S, Xu J. Recent advances and challenges in colorectal cancer: From molecular research to treatment. World J Gastroenterol. 2025;31(21):106964. doi: 10.3748/wjg.v31.i21.106964. PMID: 40538516; PMCID: PMC12175868.
  3. Parikh MS, Johnson P, Romanes JP, Freitag HE, Spring ME, Garcia-Henriquez N, et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A systematic review. Dis Colon Rectum. 2022;65(1):16-26. doi: 10.1097/DCR.0000000000002315. PMID: 34636780.
  4. Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256-66. doi: 10.1016/S1470-2045(20)30599-4. PMID: 33476595.
  5. Klempner SJ, Ryan DP. HIPEC for colorectal peritoneal metastases. Lancet Oncol. 2021;22(2):162-4. doi: 10.1016/S1470-2045(20)30693-8. PMID: 33476594.
  6. Han F, Xu Y, Li X, Song Z, Xie J, Yao J. Clinicopathological features and prognosis analysis of proximal colonic mucinous adenocarcinoma. Sci Rep. 2024;14(1):18682. doi: 10.1038/s41598-024-69916-0. PMID: 39134655; PMCID: PMC11319726.
  7. Dale W, Klepin HD, Williams GR, Alibhai SMH, Bergerot C, Brintzenhofeszoc K, et al. Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO Guideline Update. J Clin Oncol. 2023;41(26):4293-312. doi: 10.1200/JCO.23.00933. Erratum in: J Clin Oncol. 2025;43(36):3850. doi: 10.1200/JCO-25-02598. PMID: 37459573; PMCID: PMC12803700.
  8. Zhang Y, Chen Y, Huang J, Wu X, Tang R, Huang Q, et al. Mucinous histology is associated with poor prognosis in locally advanced colorectal adenocarcinoma treated with postoperative first-line adjuvant chemotherapy: A systematic review and meta-analysis. Eur J Surg Oncol. 2022;48(10):2075-81. doi: 10.1016/j.ejso.2022.06.024. PMID: 35768312.
  9. Herold Z, Acs M, Szasz AM, Olasz K, Hussong J, Mayr M, et al. Patients with metachronous peritoneal metastatic mucinous colorectal adenocarcinoma benefit more from cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) than their synchronous counterparts. Cancers (Basel). 2022;14(16):3978. doi: 10.3390/cancers14163978. PMID: 36010972; PMCID: PMC9406628.
  10. White MG, Badgwell B. Oncologic components of HIPEC: Key Question : In patients with gastric or colorectal adenocarcinoma metastatic to the peritoneum, does cytoreductive surgery (CRS) plus hyperthermic intraperitoneal perfusion with chemotherapy (HIPEC) prolong survival or increase the risk of complications relative to CRS alone? Ann Surg Oncol. 2022;29(11):6561-4. doi: 10.1245/s10434-021-11253-x. PMID: 34994900.
Middle East Journal of Cancer

Articles in Press, Accepted Manuscript
Available Online from 01 April 2027

Home

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us